Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease

Open access
Kostakoglu, Lale, Goldsmith, Stanley J., Leonard, John P., Christos, Paul, Furman, Richard R., Atasever, Tamer, Chandramouly, Angely, Verma, Sumeet, Kothari, Pratichi, Coleman, Morton · 2006 · Cancer

Abstract

BACKGROUND.: Early prediction of response to therapy may offer the potential to identify patients who will benefit from standard conventional therapy. The objective of this study was to determine the predictive value of FDG‐PET as an early response indicator after 1 cycle of chemotherapy for progression‐free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD). METHODS.: FDG‐PET was performed before, after 1 cycle, and after completion of chemotherapy in 47 patients. The patients were followed with a median follow‐up of 21 months (range, 3–47 months). PFS was compared between PET‐positive and PET‐negative patients after 1 cycle and after completion of therapy. RESULTS.: All PET‐negative patients after 1 cycle (n = 31) had sustained complete remission with a median follow‐up of 28 months. Fourteen of 16 PET‐positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months). There were 2 false‐positive results, 1 with an active infection at the biopsy site and the other in a patient who had been in remission after radiation therapy. There was good agreement between the results obtained after 1 cycle and at completion of therapy (kappa, 0.80); however, the negative predictive value was higher for FDG‐PET after 1 cycle than after completion of chemotherapy (100% vs 91.4%), although not statistically different (P = .40). CONCLUSIONS.: FDG‐PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22276

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Kostakoglu, L., Goldsmith, S. J., Leonard, J. P., Christos, P., Furman, R. R., Atasever, T., Chandramouly, A., Verma, S., Kothari, P., & Coleman, M.
Venue
Cancer
Publisher
Wiley
Published
2006-10-24
Volume
107
Issue
11
Pages
2678-2687
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2066799536
Cited by
168
References
1
FWCI
12.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. https://app.cochat.ai/papers/10.1002/cncr.22276
The paper
Kostakoglu, L., Goldsmith, S. J., Leonard, J. P., Christos, P., Furman, R. R., Atasever, T., Chandramouly, A., Verma, S., Kothari, P., & Coleman, M. (2006). FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. https://doi.org/10.1002/cncr.22276

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.